Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Data of a meta-analysis on pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia

  • Labad, Javier|||0000-0003-2214-1886
  • Montalvo, Itziar
  • González-Rodríguez, Alexandre|||0000-0003-1855-8566
  • Garcia Rizo, Clemente|||0000-0002-4855-1608
  • Crespo-Facorro, Benedicto|||0000-0003-0033-7132
  • Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
  • Palao, Diego|||0000-0002-3323-6568
The data presented in this paper describe supplementary material to the article entitled "Pharmacological treatment strategies for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia: a systematic review and meta-analysis" . Although raw data was published on the original article, additional raw data has been included in the current paper (new tables with socio-demographic and clinical characteristics of the samples of the studies included in the systematic review). Supplementary data also include the PICO scheme of the systematic review, PRISMA checklist, flow diagram, an explanation of the method for obtaining prolactin concentrations from published figures when data was only available in figures, list of the selected studies, risk of bias summary of all five randomized clinical trials evaluating the addition of aripiprazole for lowering prolactin (included in the meta-analysis in the original article). Extra analyses, figures and R code of the meta-analysis have been also included. Meta-analysis of randomized clinical trials (RCTs) considering aripiprazole addition for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia were conducted with two softwares: 1) R and the metaphor package (for the meta-analysis of the primary outcome [prolactin reduction]); 2) MedCalc version 18.11 (for the meta-analysis of the secondary outcome [withdrawal rates]). Data from a sensitivity analysis (repeating the meta-analysis with only placebo-controlled RCTs) has been also included in the current article.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Role of Sleep Quality, Trait Anxiety and Hypothalamic-Pituitary-Adrenal Axis Measures in Cognitive Abilities of Healthy Individuals

  • Labad, Javier|||0000-0003-2214-1886
  • Urretavizcaya, Mikel|||0000-0002-9746-4068
  • Monreal Ortiz, Jose Antonio|||0000-0002-0906-927X
  • Crespo, José Manuel
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Palao, Diego|||0000-0002-3323-6568
  • Menchón Magriñá, José Manuel|||0000-0002-6231-6524
  • Soria, Virginia|||0000-0001-6412-6831
  • Salvat-Pujol, Neus|||0000-0001-5320-331X
  • Armario Garcia, Antonio|||0000-0001-9524-3635
  • Cabezas, Ángel|||0000-0001-8114-0264
  • De Arriba-Arnau, Aida|||0000-0002-7877-7341
  • Nadal i Alemany, Roser|||0000-0001-8972-2525
  • Martorell, Lourdes|||0000-0003-4999-2197
Sleep plays a crucial role in cognitive processes. Sleep and wake memory consolidation seem to be regulated by glucocorticoids, pointing out the potential role of the hypothalamic-pituitary-adrenal (HPA) axis in the relationship between sleep quality and cognitive abilities. Trait anxiety is another factor that is likely to moderate the relationship between sleep and cognition, because poorer sleep quality and subtle HPA axis abnormalities have been reported in people with high trait anxiety. The current study aimed to explore whether HPA axis activity or trait anxiety moderate the relationship between sleep quality and cognitive abilities in healthy individuals. We studied 203 healthy individuals. We measured verbal and visual memory, working memory, processing speed, attention and executive function. Sleep quality was assessed with the Pittsburgh Sleep Quality Index. Trait anxiety was assessed with the State-Trait Anxiety Inventory. HPA axis measures included the cortisol awakening response (CAR), diurnal cortisol slope and cortisol levels during the day. Multiple linear regression analyses explored the relationship between sleep quality and cognition and tested potential moderating effects by HPA axis measures and trait anxiety. Poor sleep quality was associated with poorer performance in memory, processing speed and executive function tasks. In people with poorer sleep quality, a blunted CAR was associated with poorer verbal and visual., memory and executive functions, and higher cortisol levels during the day were associated with poorer processing speed. Trait anxiety was a moderator of visual memory and executive functioning. These results suggest that subtle abnormalities in the HPA axis and higher trait anxiety contribute to the relationship between lower sleep quality and poorer cognitive functioning in healthy individuals.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Glycated Haemoglobin Is Associated With Poorer Cognitive Performance in Patients With Recent-Onset Psychosis

  • Montalvo, Itziar
  • González-Rodríguez, Alexandre|||0000-0003-1855-8566
  • Cabezas, Ángel|||0000-0001-8114-0264
  • Gutiérrez-Zotes, Alfonso|||0000-0002-4858-1487
  • Solé Moix, Montserrat|||0000-0001-8871-2720
  • Algora, María José
  • Ortega, Laura
  • Martorell, Lourdes|||0000-0003-4999-2197
  • Sánchez Gistau, Vanessa|||0000-0002-8635-7144
  • Vilella, Elisabet|||0000-0002-1887-5919
  • Labad, Javier|||0000-0003-2214-1886
Glucose abnormalities and cognitive alterations are present before the onset of schizophrenia. We aimed to study whether glucose metabolism parameters are associated with cognitive functioning in recent-onset psychosis (ROP) patients while adjusting for hypothalamic-pituitary adrenal (HPA) axis measures. Sixty ROP outpatients and 50 healthy subjects (HS) were studied. Cognitive function was assessed with the MATRICS Consensus Cognitive Battery. Glycated haemoglobin (HbA1), glucose, insulin, and C-peptide levels were determined in plasma. The HOMA-insulin resistance index was calculated. Salivary samples were obtained at home on another day to assess the cortisol awakening response and cortisol levels during the day. Univariate analyses were conducted to explore the association between glucose metabolism parameters and cognitive tasks. For those parameters that were more clearly associated with the cognitive outcome, multiple linear regression analyses were conducted to adjust for covariates. Each cognitive task was considered the dependent variable. Covariates were age, sex, education level, diagnosis, antipsychotic and benzodiazepine treatment, body mass index (BMI), smoking, and HPA axis measures. Potential interactions between diagnosis and glucose parameters were tested. There were no significant differences in HPA axis measures or glucose parameters, with the exception of C-peptide (that was higher in ROP patients), between groups. ROP patients had a lower performance than HS in all cognitive tasks (p < 0.01 for all tasks). Of all glucose metabolism parameters, HbA1c levels were more clearly associated with cognitive impairment in cognitive tasks dealing with executive functions and visual memory in both ROP patients and HS. Multivariate analyses found a significant negative association between HbA1c and cognitive functioning in five cognitive tasks dealing with executive functions, visual memory and attention/vigilance (a ROP diagnosis by HbA1 negative interaction was found in this latter cognitive domain, suggesting that HBA1 levels are associated with impaired attention only in ROP patients). Our study found that HbA1 was negatively associated with cognitive functioning in both ROP patients and HS in tasks dealing with executive functions and visual memory. In ROP patients, HbA1 was also associated with impaired attention. These results were independent of BMI and measures of HPA axis activity.